Whole-genome landscapes of major melanoma subtypes - PubMed (original) (raw)
. 2017 May 11;545(7653):175-180.
doi: 10.1038/nature22071. Epub 2017 May 3.
James S Wilmott 1 3, Nicola Waddell 2 4, Peter A Johansson 2, Matthew A Field 5, Katia Nones 2 4, Ann-Marie Patch 2 4, Hojabr Kakavand 3, Ludmil B Alexandrov 6, Hazel Burke 1, Valerie Jakrot 1, Stephen Kazakoff 2 4, Oliver Holmes 2 4, Conrad Leonard 2 4, Radhakrishnan Sabarinathan 7 8, Loris Mularoni 7 8, Scott Wood 2 4, Qinying Xu 2 4, Nick Waddell 4, Varsha Tembe 9, Gulietta M Pupo 9, Ricardo De Paoli-Iseppi 3, Ricardo E Vilain 3, Ping Shang 3, Loretta M S Lau 10, Rebecca A Dagg 11, Sarah-Jane Schramm 9, Antonia Pritchard 2, Ken Dutton-Regester 2, Felicity Newell 2, Anna Fitzgerald 12, Catherine A Shang 12, Sean M Grimmond 13, Hilda A Pickett 10, Jean Y Yang 14, Jonathan R Stretch 1, Andreas Behren 15, Richard F Kefford 1 16, Peter Hersey 1 17, Georgina V Long 1 18, Jonathan Cebon 15, Mark Shackleton 19, Andrew J Spillane 1, Robyn P M Saw 1, Núria López-Bigas 7 8 20, John V Pearson 2 4, John F Thompson 1, Richard A Scolyer 1 3 21, Graham J Mann 1 9
Affiliations
- PMID: 28467829
- DOI: 10.1038/nature22071
Whole-genome landscapes of major melanoma subtypes
Nicholas K Hayward et al. Nature. 2017.
Abstract
Melanoma of the skin is a common cancer only in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet (acral sites) in people throughout the world. Here we report analysis of whole-genome sequences from cutaneous, acral and mucosal subtypes of melanoma. The heavily mutated landscape of coding and non-coding mutations in cutaneous melanoma resolved novel signatures of mutagenesis attributable to ultraviolet radiation. However, acral and mucosal melanomas were dominated by structural changes and mutation signatures of unknown aetiology, not previously identified in melanoma. The number of genes affected by recurrent mutations disrupting non-coding sequences was similar to that affected by recurrent mutations to coding sequences. Significantly mutated genes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in acral melanoma and SF3B1 in mucosal melanoma. Mutations affecting the TERT promoter were the most frequent of all; however, neither they nor ATRX mutations, which correlate with alternative telomere lengthening, were associated with greater telomere length. Most melanomas had potentially actionable mutations, most in components of the mitogen-activated protein kinase and phosphoinositol kinase pathways. The whole-genome mutation landscape of melanoma reveals diverse carcinogenic processes across its subtypes, some unrelated to sun exposure, and extends potential involvement of the non-coding genome in its pathogenesis.
Comment in
- Filling the gaps in the genomic catalogue of melanoma subtypes.
Shain AH, Bastian BC. Shain AH, et al. Pigment Cell Melanoma Res. 2017 Jan;30(6):508-509. doi: 10.1111/pcmr.12612. Epub 2017 Oct 21. Pigment Cell Melanoma Res. 2017. PMID: 28656717 No abstract available.
Similar articles
- [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN, Tsyganova IV, Lushnikova AA, Ponkratova DA, Anurova OA, Cheremushkin EA, Mikhailova IN, Demidov LV. Mazurenko NN, et al. Mol Biol (Mosk). 2015 Nov-Dec;49(6):1022-9. doi: 10.7868/S0026898415060166. Mol Biol (Mosk). 2015. PMID: 26710785 Russian. - Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
Manrique-Silva E, Rachakonda S, Millán-Esteban D, García-Casado Z, Requena C, Través V, Kumar R, Nagore E. Manrique-Silva E, et al. Br J Dermatol. 2021 Mar;184(3):504-513. doi: 10.1111/bjd.19297. Epub 2020 Jul 21. Br J Dermatol. 2021. PMID: 32506424 - Distinct sets of genetic alterations in melanoma.
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Curtin JA, et al. N Engl J Med. 2005 Nov 17;353(20):2135-47. doi: 10.1056/NEJMoa050092. N Engl J Med. 2005. PMID: 16291983 - Melanoma.
Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A. Schadendorf D, et al. Nat Rev Dis Primers. 2015 Apr 23;1:15003. doi: 10.1038/nrdp.2015.3. Nat Rev Dis Primers. 2015. PMID: 27188223 Review. - Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR, Montironi R, Lopez-Beltran A, Post KM, MacLennan GT, Cheng L. Bradish JR, et al. Future Oncol. 2013 Feb;9(2):245-53. doi: 10.2217/fon.12.179. Future Oncol. 2013. PMID: 23414474 Review.
Cited by
- Mechanistic basis of atypical TERT promoter mutations.
Elliott K, Singh VK, Bäckerholm A, Ögren L, Lindberg M, Soczek KM, Hoberg E, Luijts T, Van den Eynden J, Falkenberg M, Doudna J, Ståhlberg A, Larsson E. Elliott K, et al. Nat Commun. 2024 Nov 18;15(1):9965. doi: 10.1038/s41467-024-54158-5. Nat Commun. 2024. PMID: 39557834 - MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.
Cai X, Lin J, Li C, Xu T, Chen C, Lan B, Wang X, Bai S, Huang Y, Zhang H, Si L, Chen Y. Cai X, et al. BMC Cancer. 2024 Nov 11;24(1):1384. doi: 10.1186/s12885-024-13163-z. BMC Cancer. 2024. PMID: 39528978 Free PMC article. - Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target.
Böcker M, Chatziioannou E, Niessner H, Hirn C, Busch C, Ikenberg K, Kalbacher H, Handgretinger R, Sinnberg T. Böcker M, et al. Int J Mol Sci. 2024 Nov 4;25(21):11853. doi: 10.3390/ijms252111853. Int J Mol Sci. 2024. PMID: 39519404 Free PMC article. - Enhancer of Zeste Homolog 2 Protects Mucosal Melanoma from Ferroptosis via the KLF14-SLC7A11 Signaling Pathway.
Du H, Hou L, Yu H, Zhang F, Tong K, Wu X, Zhang Z, Liu K, Miao X, Guo W, Guo J, Kong Y. Du H, et al. Cancers (Basel). 2024 Oct 30;16(21):3660. doi: 10.3390/cancers16213660. Cancers (Basel). 2024. PMID: 39518098 Free PMC article. - Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma.
Valencia G, Roque K, Rioja P, Huamán JA, Colomo V, Sánchez J, Calle C, Mantilla R, Morante Z, Fuentes H, Vidaurre T, Neciosup S, De Mello RA, Gómez HL, Fernández-Díaz AB, Berrocal A, Castaneda C. Valencia G, et al. Onco Targets Ther. 2024 Nov 2;17:871-886. doi: 10.2147/OTT.S483753. eCollection 2024. Onco Targets Ther. 2024. PMID: 39507408 Free PMC article.
References
- Nat Genet. 2015 Dec;47(12):1408-10 - PubMed
- Nat Genet. 2015 Sep;47(9):996-1002 - PubMed
- Oncotarget. 2014 May 30;5(10):2912-7 - PubMed
- Nucleic Acids Res. 2013 Jan;41(2):e34 - PubMed
- Bioinformatics. 2014 Apr 1;30(7):1015-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous